You searched for stem cell biotech - Page 36 of 39

Steven Pinker interview: case against bioethocrats & CRISPR germline ban

August 10, 2015 / Professor Paul Knoepfler, Ph.D. / 15 Comments

CRISPR-Cas9 gene editing technology is red-hot right now and I’ve been doing interviews with various thought leaders on it, which today includes Steven Pinker. This technology has great power for research in the lab and there are hypothetical transformative clinical applications of CRISPR too. The latter efforts could include experimental attempts at reversal of disease-causing […]

Steven Pinker interview: case against bioethocrats & CRISPR germline ban Read More »

Global transhumanism leader Natasha Vita-More on human germline modification

August 3, 2015 / Professor Paul Knoepfler, Ph.D. / 1 Comment

In my continuing series of conversations with thought leaders related to heritable human modification, today’s post is an interview with Natasha Vita-More, a pioneer in the transhumanism movement and Chairman of the Board of Directors of Humanity+ (H+), the global transhumanist organization. Where do you see transhumanism today? Has it changed over the years? What

Global transhumanism leader Natasha Vita-More on human germline modification Read More »

Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next?

May 20, 2015 / Chris Scott / 1 Comment

A decade ago I wrote an article in the journal Nature Biotechnology about the rise of a new gene editing technology called zinc finger nucleases (ZNF). It was one of those “drumbeat” discoveries: at the time, my sense was it would revolutionize how we deliver genes to cells and tissues, and profoundly change the way

Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next? Read More »

Was Fujifilm CDI acquisition a good move by the companies?

March 31, 2015 / Professor Paul Knoepfler, Ph.D. / 4 Comments

The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did

Was Fujifilm CDI acquisition a good move by the companies? Read More »

ARM Asks FDA for Clarification on Draft Guidance on Minimal Manipulation

March 4, 2015 / Professor Paul Knoepfler, Ph.D.

In the last few months the FDA has taken steps toward crystalizing regulatory oversight of stem cell and more broadly cell and tissue-based therapies. These steps come in the form of several draft guidances (see here, here, and here) . The Alliance for Regenerative Medicine (ARM) has responded to the draft guidance on Minimal Manipulation. For example, ARM has

ARM Asks FDA for Clarification on Draft Guidance on Minimal Manipulation Read More »

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

March 2, 2015 / Professor Paul Knoepfler, Ph.D.

VC-01-post-implant-final1-e1503703572933, viacyte

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

Radical Vision for CIRM Future: Interview with New Prez Mills

December 5, 2014 / Professor Paul Knoepfler, Ph.D.

Change is in the air for the California stem cell agency, CIRM. It has a new President, Randy Mills, and CIRM is soon going to be like a new agency too. I recently did an interview with Mills that illuminates some of the big changes that are imminent. I also asked him what his favorite

Radical Vision for CIRM Future: Interview with New Prez Mills Read More »

Cloning Factory in China Has Familiar Partner: Hwang Woo-Suk

December 2, 2014 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Cloning of animals is becoming a big, global business, and Hwang Woo-Suk is a major player here. Hwang Woo-Suk and animal cloning It turns out that this reproductive cloning of animals goes well beyond making duplicates of pets for sentimental customers at $100,000 a copy. Cloning of livestock by agribusinesses is becoming fairly common. Some

Cloning Factory in China Has Familiar Partner: Hwang Woo-Suk Read More »

Clinicaltrials.gov Mission At Risk From Proliferating For-Profit Trials

October 14, 2014 / Professor Paul Knoepfler, Ph.D. / 3 Comments

It’s hard to even imagine the world of investigative medicine without the wonderful resource of Clinicaltrials.gov, the global hub for clinical trial listings. I recently interviewed the Director of Clinicaltrials.gov, Dr. Deborah Zarin here, which is a fascinating read. As great as Clinicaltrials.gov is as a resource, unfortunately it faces a new, rapidly growing problem that is a serious

Clinicaltrials.gov Mission At Risk From Proliferating For-Profit Trials Read More »

CIRM 2.0 Should Include Bridges Training Program

September 25, 2014 / Professor Paul Knoepfler, Ph.D. / 5 Comments

The California Stem Cell Agency CIRM seems to be in budget cutting mode these days, which from a general perspective makes sense as CIRM seeks to continue operating on its remaining funding through a longer period of time as far out as to 2020. However, not all cuts are necessarily positive. For example, CIRM reportedly (note: many

CIRM 2.0 Should Include Bridges Training Program Read More »

Search Results for: stem cell biotech